Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 4/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155469 | 0.83 | MEN1 (0.58) | KMT2AMEN1HTTNPC1GAA | |
| SCHEMBL24155504 | 0.80 | DYRK1A (0.43) | KMT2AMEN1HTTEGFRBTK | |
| SCHEMBL24156289 | 0.79 | KMT2A (0.48) | KMT2AMEN1HTTEGFRBTK | |
| SCHEMBL30483681 | 0.76 | MAP4K4 (0.46) | KMT2AMEN1HTTEGFRBTK | |
| SCHEMBL22405023 | 0.76 | MAOB (0.44) | KMT2AMEN1HTTEGFRBTK | |
| SCHEMBL22534733 | 0.76 | MAP4K4 (0.46) | KMT2AMEN1HTTEGFRBTK | |
| SCHEMBL24155820 | 0.76 | KMT2A (0.54) | KMT2AMEN1HTTEGFRBTK | |
| SCHEMBL24155819 | 0.76 | KMT2A (0.43) | KMT2AMEN1HTTEGFRBTK | |
| SCHEMBL24155498 | 0.74 | MEN1 (0.46) | KMT2AMEN1HTTEGFRBTK | |
| SCHEMBL22404959 | 0.74 | ACACB (0.43) | KMT2AMEN1HTTEGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | KMT2A 279/4885MEN1 450/4885HTT 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.